ArticleThe Journal of infectious diseases2025
Circulating Hepatitis B Virus (HBV) RNA and Conventional Markers in Treatment-Naive Persons With HBV in Senegal.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection affects approximately 10% of the general population in West Africa. Circulating HBV RNA may help improve the characterization of HBV disease and prognosis. We aimed to evaluate the associations between HBV RNA and conventional biomarkers of HBV replication in the Senegalese Hepatitis B Cohort Study (SEN-B).
methodsWe included all treatment-naive, human immunodeficiency virus-negative participants of SEN-B with chronic HBV infection confirmed by a quantitative hepatitis B surface antigen (HBsAg) >0.05 IU/mL. We quantified HBV RNA, HBV DNA, and HBsAg levels and evaluated associations between those markers stratified by HBV infection phase, alanine aminotransferase level, and liver fibrosis stage.
resultsOf 719 participants, 17 (2.4%) were hepatitis B e antigen (HBeAg)-positive (EP), 620 (86.2%) were classified as HBeAg-negative chronic infection (ENCI), and 82 (11.4%) were classified as HBeAg-negative chronic hepatitis (ENCH). HBV RNA was undetectable in 361 (49.8%) participants, and detectable but unquantifiable in 188 (26.1%). HBV RNA levels correlated moderately with HBV DNA levels in EP (ρ = 0.58, P = .01) and ENCH (ρ = 0.54, P < .001) and weakly in ENCI (ρ = 0.39, P < .001). HBsAg levels were only significantly correlated with HBV RNA levels in the ENCH group (ρ = -0.22, P = .05). In multivariable logistic regression, HBV RNA levels and HBV RNA to HBV DNA ratio were independently associated with significant liver fibrosis.
conclusionsIn our cohort of treatment-naive persons with HBV from Senegal, approximately 50% had undetectable HBV RNA levels. HBV RNA levels correlated with HBV DNA but not HBsAg levels in all phases of HBV infection and may provide an additional tool to assess HBV disease phase and activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.